Akorn-Strides, LLC Announces FDA Approval for Rifampin for Injection USP, 600 mg/Vial

May 23, 2008 |

1 min read

Twitter
LinkedIn
Facebook
Email
Print

BUFFALO GROVE, Ill.--(BUSINESS WIRE)--Akorn-Strides, LLC today announced the approval of an ANDA for Rifampin for Injection USP, 600 mg/vial. This is the first lyophilized Injectable product approval for the Joint Venture.

Twitter
LinkedIn
Facebook
Email
Print

FDA Approvals

Food and Drug Administration (FDA)